On a corporate action affecting ordinary shares of bluebird bio, Inc. (BLUE)

On February 6, 2025, bluebird bio, Inc. entered into a merger agreement under which it will be acquired by Beacon Parent Holdings, bluebird bio, Inc. stockholders will receive $3.00 in cash and one contingent value right (CVR) representing the right to receive a non-tradeable contingent payment of up to $6.84 in cash for each share of bluebird bio, Inc. that they own. Transaction is expected to close in the first half of 2025. For more details, please, refer to the company’s website.

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.